View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 10, 2011

Svelte treats first patient in DIRECT study

Svelte Medical Systems has treated its first patient at Auckland City Hospital in Auckland, New Zealand, in the DIRECT study.

Svelte Medical Systems has treated its first patient at Auckland City Hospital in Auckland, New Zealand, in the DIRECT study.

DIRECT is a first-in-man, multicentre clinical study that will involve 30 patients to evaluate the feasibility of Svelte’s All-In-One system.

The CE marked All-In-One system is a low profile flexible drug-eluting system that integrates a thin-strut cobalt chromium stent with a fully bio-erodable drug carrier and the drug Sirolimus (rapamycin).

Svelte’s drug delivery system incorporates a proprietary balloon control band technology providing uniform and controlled balloon growth, facilitating physicians to ‘direct-stent’ coronary artery lesions, while reducing procedure time and cost.

The company plans to market its drug-eluting stent on a conventional rapid-exchange delivery platform, and to expand it into larger studies in 2012.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management